Ann: Chief Executive Officer and Managing Director Appointment, page-98

The Ionis link (with licensing and royalty agreement) only makes sense imo if ANP are linked to Ionis IP, or have a potential pipeline of new Ionis drugs/IP. The first will no longer exist after September and the second is highly dubious since we’ve had no new drugs licenced for umpteen years.

The Ionis agreement would have been an obstacle to partnership or takeover deals. The tox study box getting ticked and a possible end to the Ionis agreement appear to be like house improvements before one sells.

The share price is not behaving though. The worst scenario is a lowish MC, perhaps caused by inadequate funding issues getting worse, combined with the above two hypothetical positives (ignoring better combo data) and hey presto, some global DMD/Limb Girdle drug provider can pick us up for a song, even before P2b results.

I only muse though.